SecBot SecBot
SECBOTREPLAY Home › Report › SLNO

SLNO · Neurocrine Biosciences completed its acquisition of Soleno Therapeutics…

SOLENO THERAPEUTICS INC · 8-K filed May 18, 2026 at 09:06 ET

At the news

BULLISHIMPACT 8/10

8-K filed May 18, 2026 at 09:06 ET

Neurocrine Biosciences completed its acquisition of Soleno Therapeutics on May 18, 2026, paying $53.00 per share in cash. The tender offer closed with 46,356,114 shares (88.9% of outstanding) tendered, followed by a short-form merger under Section 251(h) of the DGCL. SLNO common stock has been delisted from Nasdaq and the company will deregister its securities. This filing confirms the deal has closed, existing SLNO shareholders who did not tender in the offer will receive $53.00 per share in the merger.

  • Acquisition by Neurocrine Biosciences at $53.00 per share in cash
  • 88.9% of shares tendered in the offer (46,356,114 shares)
  • Tender offer expired May 15, 2026; merger completed May 18, 2026
  • SLNO common stock delisted from Nasdaq; Form 25 and Form 15 filings initiated

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access